Related Experiment Video
Updated: Jun 12, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
Ravulizumab administration for relapse prevention in atypical hemolytic uremic syndrome with a CFH variant: A case
Mako Hashimoto1, Yuki Fujioka1, Ayano Saito1
1Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan.
Abstract:
Atypical hemolytic uremic syndrome (aHUS) is a rare cause of thrombotic microangiopathy (TMA). When aHUS cannot be excluded, diagnostic treatment with anti-C5 antibody agents should be considered. We report a patient with a novel heterozygous complement factor H (CFH) variant, p.Glu1198Asp (c.3594A>T), who received ravulizumab three months after disease onset. Ravulizumab was administered for relapse prevention in the chronic phase, and no recurrence of thrombotic microangiopathy was observed during the follow-up.
Related Concept Videos
Respiratory Syncytial Virus Disease
Hypersensitivity Reactions: Cytolytic Reactions
Cytomegalovirus Disease
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Hypersensitivity Reactions: Immune-Complex Reactions
Continuous Renal Replacement Therapy